Prognostic performance of different parameters for the identification of patients with severe disease (primary outcome) and optimal therapy response (secondary outcome)
| Cut-off value | AUC (95% CI) | Sensitivity (%, 95% CI) | Specificity (%, 95% CI) | NPV (%, 95% CI) | PPV (%, 95% CI) | OR (95% CI) | |
| Identification of patients at a severe disease state (primary outcome); n=17 | |||||||
| MR-proANP pmol·L−1 | 227 | 0.91 (0.86–0.97) | 93 (68–100) | 80 (70–88) | 99 (92–100) | 43 (33–54) | 56 (6.9–454.3) |
| Copeptin pmol·L−1 | 10.9 | 0.70 (0.57–0.83) | 67 (38–88) | 71 (61–80) | 93 (86–96) | 27 (19–38) | 1.5 (1.2–1.9) |
| NT-proBNP ng·L−1 | 1050 | 0.89 (0.82–0.96) | 100 (79–100) | 65 (54–75) | 100 (100) | 31 (26–38) | 4.9 (1.5–15.8) |
| eGFR mL·min−1·m−2 | 66 | 0.68 (0.52–0.83) | 53 (28–77) | 82 (73–90) | 91 (87–95) | 33 (21–48) | 5.3 (1.8–15.8) |
| 6-min walk distance m | 355 | 0.72 (0.52–0.92) | 67 (30–93) | 78 (66–88) | 94 (85–97) | 33 (20–49) | 7.2 (1.5–32.9) |
| WHO functional class | III | 0.67 (0.53–0.81) | 100 (80–100) | 11 (5–19) | 100 (100) | 15 (5–19) | 1.2 (1.1–1.3) |
| TAPSE mm | 18 | 0.70 (0.54–0.85) | 67 (86–96) | 69 (57–79) | 93 (86–96) | 26 (18–36) | 4.4 (1.4–14.3) |
| Identification of optimal therapy responders (secondary outcome); n=53 | |||||||
| MR-proANP pmol·L−1 | 123 | 0.70 (0.60–0.79) | 87 (74–94) | 45 (31–59) | 82 (68–91) | 53 (47–59) | 5.2 (2.0–13.5) |
| Copeptin pmol·L−1 | 10.1 | 0.58 (0.47–0.69) | 81 (68–91) | 39 (27–53) | 74 (60–85) | 49 (43–55) | 2.8 (1.2–6.7) |
| NT-proBNP ng·L−1 | 369 | 0.64 (0.53–0.75) | 96 (85–100) | 28 (16–43) | 90 (68–97) | 49 (44–54) | 8.4 (1.8–39.2) |
| eGFR mL·min−1·m−2 | 89 | 0.66 (0.56–0.77) | 68 (54–80) | 66 (52–78) | 74 (65–81) | 59 (49–69) | 4.1 (1.9–9.2) |
| 6-min walk distance m | 494 | 0.72 (0.61–0.84) | 63 (45–79) | 77 (61–88) | 74 (64–82) | 66 (52–78) | 5.6 (2.1–15.0) |
| WHO functional class | III | 0.65 (0.55–0.76) | 96 (87–100) | 14 (6–26) | 84 (54–96) | 45 (42–48) | 4.3 (0.86–21.0) |
| TAPSE mm | 18 | 0.58 (0.45–0.70) | 60 (43–75) | 24 (12–45) | 45 (30–61) | 36 (30–44) | 0.47 (0.18–1.2) |
AUC: area under the curve; CI: confidence interval; NPV: negative predictive values; PPV: positive predictive values; OR: odds ratio; MR-proANP: mid-regional pro-atrial natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; eGFR: estimated glomerular filtration rate; WHO: World Health Organization; TAPSE: tricuspid annular plan systolic excursion.